Cyclopentyl (3-(2-Methoxy-4-((O-Tolylsulfonyl)Carbamoyl)Benzyl)-1-Methyl-1H-Indol-5-Yl)Carbamate (3-(2-甲氧基-4-((邻甲苯基磺酰基)氨基甲酰基)苄基)-1-甲基-1H-吲哚-5-基)氨基甲酸环戊酯

CAS 107753-78-6 MFCD00864775

化学结构图

107753-78-6
SMILES: CC1C=CC=CC=1S(=O)(=O)NC(=O)C1C=C(OC)C(CC2=CN(C)C3C=CC(=CC2=3)NC(=O)OC2CCCC2)=CC=1

化学属性

Mol. FormulaC31H33N3O6S
Mol. Weight576
Appearance 从甲醇得白色固体,熔点138~140℃。
Melting Point139°C

别名和识别编码

Chemical NameCyclopentyl (3-(2-Methoxy-4-((O-Tolylsulfonyl)Carbamoyl)Benzyl)-1-Methyl-1H-Indol-5-Yl)Carbamate
CAS Number107753-78-6
Synonym 4-[5-(Cyclopentyloxycarbonylamino)-1-methyl-1H-indol-3-ylmethyl]-3-methoxy-N-(2-methylphenylsulfonyl)benzamide Carbamic acid, [3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]-, cyclopentyl ester Cyclopentyl 3-[2-methoxy-4-[(o-tolylsulfonyl)carbamoyl]benzyl]-1-met Cyclopentyl N-[3-{[2-methoxy-4-[(2-methylphenyl) sulfonylcarbamoyl]phenyl]methyl}-1-methyl-indol-5-yl]carbam Cyclopentyl [3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-indol-5-yl]aminoformate IC-204219 ICI-2204219 N-[3-[[2-Methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]carbamic acid cyclopentyl ester Vanticon ZAFIRLUKAST [3-[2-甲氧基-4-[(2-甲苯基)磺酰胺基甲酰基]苄基]-1-甲基-吲哚-5-基]氨基甲酸环戊酯 [3-[[2-Methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-y1]carbamic acid eyclopent [3-[[2-Methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]carbamic Acid Cyclopentyl Ester [3-[[2-Methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]carbamic Acid Cyclopentyl Ester, ICI-2204219, Accolate [3-[[2-Methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]carbamic a cyclopentyl [3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-indol-5-yl]aminoformate cyclopentyl n-[3-{[2-methoxy-4-[(2-methylphenyl) sulfonylcarbamoyl]phenyl]methyl}-1-methyl-indol-5-yl]carbamate {} {Chemicalbook} 扎鲁司特 扎鲁斯特
MDL NumberMFCD00864775
Chemical Name Translation(3-(2-甲氧基-4-((邻甲苯基磺酰基)氨基甲酰基)苄基)-1-甲基-1H-吲哚-5-基)氨基甲酸环戊酯
PubChem Substance ID253661584
Reaxys-RN3641829
Merck Number10108
信息真实价格透明    资金保障    专业采购外包团队在线服务   
信息真实价格透明    资金保障    专业采购外包团队在线服务   
品牌质保精细包装    现货库存    一流品牌服务   

分类

  • {Chemicalbook} 药物: 呼吸系统用药: 平喘药
  • Approved Therapeutics/Drug Candidates, Arachidonic Acid Cascade, AstraZeneca, Bioactive Small Molecules, Cell Biology, Cell Signaling and Neuroscience, Leukotrienes, Lipids in Cell Signaling, Z
  • {SNA} Approved Therapeutics/Drug Candidates, Arachidonic Acid Cascade, AstraZeneca, Bioactive Small Molecule Alphabetical Index, Diversification Ready Pharma-Developed Compounds, Leukotrienes, Lipids in Cell Signaling, Z, 生物活性小分子, 细胞信号转导和神经科学, 细胞生物学
  • {SNA} Approved Therapeutics/Drug Candidates, Arachidonic Acid Cascade, AstraZeneca, Bioactive Small Molecules,

产品应用

  • A potent, selective and orally active cysteinyl leukotriene type 1 receptor antagonist. Used as an antiasthmatic.

相关文献及参考

  • [2]. Gunning WT, et al. Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res. 2002 Aug 1;62(15):4199-201.
  • [3]. Lei C, et al. Zafirlukast attenuates advanced glycation end-products (AGEs)-induced degradation of articular extracellular matrix (ECM). Int Immunopharmacol. 2019;68:68-73.
  • Findlay, S.R., et al.: J. Allergy Clin. Immunol., 89, 1040 (1992),
  • Krell, R.D., et al.: Am. Rev. Respir. Dis., 141, 978 (1990),
  • Matassa, V.G., et al.: J. Med. Chem., 33, 1781 (1990),
  • Merck 14 ,10108
  • Schain, F., et al Int. J. Cancer 123 , 2285-2293, (2008)
  • Scuderi, N., et al Int. J. Immunopharmacol. 20 , 577-584, (2007)
  • Woszczek, G., et al J. Immunol. 184 , 2219-2225, (2010)
  • [1]. Finnerty JP, et al. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D 4 receptor antagonist. Am Rev Respir Dis. 1992 Apr;14

安全信息

WGK Germany3
Hazard statements
  • H413 Maycauselonglastingharmfuleffectstoaquaticlife 可能对水生生物造成长期持续有害影响。
RTECSFB3966200

其他信息

  • MSDS 信息:Cyclopentyl [3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-indol-5-yl]aminoformate(107753-78-6).msds
  • 上游原料:四氢呋喃 --> 氢化钠 --> 1,4-二氧六环 --> 碘甲烷 --> N-甲基吗啡啉 --> 5-硝基吲哚 --> 10%钯碳 --> 钯碳催化剂 --> 3-甲氧基苯甲酸甲酯
  • 方法一:5-硝基吲哚(I,5.0g,30.8mmol)和4-(溴甲基)-3-甲氧基苯甲酸甲酯(Ⅱ,7.99g,30.8mmo1)溶于30ml二氧六环,在氮气保护和搅拌下加入氧化银(7.15g,30.8mmo1),在60℃下加热20h。减压蒸出溶剂,加入50ml乙酸乙酯。过滤,滤液浓缩,再用层析分离,以3:7的乙酸乙酯-己烷洗脱。得到的黄色油状物再用二氯甲烷-己烷结晶,得4.6g化合物(Ⅲ),收率45%,熔点153~155℃。 在氮气保护下,将化合物(Ⅲ)(0.44g,1.29mmo1)加到已游离的氢化钠(0.031g,1.29mmo1)在100ml干燥四氢呋喃的悬浮液中,在10min后再加入碘甲烷(0.18g,1.29mmo1),反应30min。倾入30ml 1mol/L盐酸,用乙酸乙酯(2×50ml)提取。提取液用饱和盐水洗,干燥,浓缩。经层析分离,以50:45:5的己烷一二氯甲烷-乙酸乙酯洗脱,得到的黄色油状物经二氯甲烷和己烷的混合液结晶,得0.33g化合物(Ⅳ),收率72%,熔点144~146℃。 化合物(Ⅳ)(0.56g,1.57mmol)溶于30ml四氢呋喃,加入0.1g10%钯-碳催化剂,在0.345MPa的氢压下加氢2h。过滤,滤液浓缩,再经层析提纯,以1:1的乙酸乙酯-己烷洗脱,得0.5g化合物(V),收率98%。 化合物(V)(0.25g,0.77mmo1)和N-甲基吗啉(0.77mmo1)溶于3ml二氯甲烷,在氮气保护下加入氯甲酸环戊基酯(0.11g,0.77mmo1),搅拌2h。倾入1mol/L盐酸,用乙酸乙酯提取。提取液用饱和盐水洗,干燥,浓缩。剩余黏稠油状物用层析提纯,以3:7的乙酸乙酯-己烷洗脱,得0.25g化合物(Ⅵ),收率74%。 化合物(Ⅵ)用氢氧化锂在室温进行水解,得到化合物(Ⅶ)。(Ⅶ)和邻甲基苯磺酰胺,在1-[3-(二甲胺基)丙基]-3-乙基碳化二亚胺盐酸盐和4-(二甲胺基)吡啶存在下,在二氯甲烷中缩合,可得扎夫司特,收率69%,熔点138~140℃。
  • MOL 文件:107753-78-6.mol
  • 用途一:白三烯拮抗剂。用于治疗哮喘。

系列性分类


相关产品推荐